Quadruple therapy: the golden bullet or a drug too far?
Moayyedi
P
P
Gastroenterology Unit, Leeds General Infirmary, UK.
D000863:Antacids / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D015738:Famotidine / Q000008:administration & dosage / Q000627:therapeutic use*; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008795:Metronidazole / Q000008:administration & dosage / Q000627:therapeutic use*; D009853:Omeprazole / Q000008:administration & dosage / Q000627:therapeutic use*; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D010352:Patient Dropouts; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000382:microbiology; D054328:Proton Pump Inhibitors; D012107:Research Design; D013752:Tetracycline / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
D000863:Antacids; D004791:Enzyme Inhibitors; D009942:Organometallic Compounds; D054328:Proton Pump Inhibitors; D008795:Metronidazole; D015738:Famotidine; D013752:Tetracycline; C002791:bismuth tripotassium dicitrate; D009853:Omeprazole